The relationship of prognosis to surgery and pathologic characteristics of stage IV (M0) gastric cancer patients

2010 ◽  
Vol 29 (4) ◽  
pp. 355-358 ◽  
Author(s):  
Ying-Wei Xue ◽  
Yu-Zhe Wei
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Stage Iv ◽  
Gastric Cancer Patients ◽  
Relationship Of ◽  
The Relationship

scholarly journals The relationship between survival gastric cancer patients and neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio diagnosed before surgery

2020 ◽  
Author(s):  
Sareh Mohammadi ◽  
Zeinab Veisi ◽  
Mohammad Moazeni ◽  
Soleiman Kheiri ◽  
Zahra Lorigooini ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Patient Survival ◽  
Neutrophil To Lymphocyte Ratio ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Gastric Cancer Patients ◽  
Relationship Of ◽  
The Relationship

Abstract Aim: This study aims to investigate the relationship of two prognostic factors NLR and PLR to patient survival in gastric cancer patients diagnosed before surgery.Background: Due to the high prevalence of gastric cancer and the lack of appropriate prognostic factors, most patients are diagnosed at advanced stages of the disease. Therefore, this study aimed to determine the appropriate prognostic factor investigated investigate the relationship of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in gastric cancer patients.Methods: This retrospective study was performed on all gastric cancer patients referred to Kashani Hospital of Shahrekord (Chaharmahal and Bakhtiari province) in 2011-2016. Demographic and biological variables such as NLR and PLR were evaluated. Patient survival was calculated by subtracting the date at disease diagnosis (using endoscopy) from the date at death and expressed in month. Data was analyzed by SPSS software.Results: The mean age of patients was 63.79 ± 15.03 (range: 10-92) years. 76% of patients were male and the rest were female. Only NLR had significant effect on survival (P < 0.05) and PLR had no significant effect on survival (P > 0.05).Conclusion: With the increase in NLR by one point, the risk of death in gastric cancer patients increased by 18%. In other words, with increase in NLR, survival rate of gastric cancer after surgery significantly decreased. It is suggested that further studies be conducted with a more statistical population to ensure the reproducibility of the results of the present study.

DETERMINATION OF P53 GENE CODON 72 POLYMORPHISMS IN PATIENTS WITH GASTRIC CANCER

2013 ◽  
pp. 11-17
Author(s):  
Thi Tuy Ha Nguyen ◽  
Thi Minh Thi Ha
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
P53 Gene ◽  
Diffuse Gastric Cancer ◽  
Codon 72 ◽  
Cancer Group ◽  
Pcr Rflp ◽  
Gastric Cancer Patients ◽  
The Relationship

Background: The role of p53 gene in the gastric cancer is still controversial. This study is aimed at determining the rate of the p53 gene codon 72 polymorphisms in gastric cancer patients and evaluating the relationship between these polymorphisms and endoscopic and histopathological features of gastric cancer. Patients and methods: Sixty eight patients with gastric cancer (cases) and one hundred and thirty six patients without gastric cancer (controls) were enrolled. p53 gene codon 72 polymorphisms were determined by PCR-RFLP technique with DNA extracted from samples of gastric tissue. Results: In the group of gastric cancer, Arginine/Argnine, Arginine/Proline and Proline/Proline genotypes were found in 29.4%, 42.7% and 27.9%, respectively. The differences of rates were not statistically significant between cases and controls (p > 0,05). In males, the Proline/Proline genotype was found in 38.1% in patients with gastric cancer and more frequent in patients without gastric cancer (15.7%, p = 0,01). An analysis of ROC curve showed that the cut-off was the age of 52 in the Proline/Proline genotype, but it was 65 years old in the Arginine/Proline genotype. The Proline/Proline genotype was found in 41.9% in Borrmann III/IV gastric cancer, this rate was higher than Borrmann I/II gastric cancer (16.2%, p = 0.037) and also higher than controls (18.4%, p = 0,01). The rate of Proline/Proline genotype was 41.7% in the diffuse gastric cancer, it was higher than in controls (p = 0,023). Conclusion: No significative difference of rate was found in genotypes between gastric cancer group and controls. However, there was the relationship between Proline/Proline genotype and gastric cancer in males, Borrmann types of gastric cancer, the diffuse gastric cancer. Key words: polymorphism, codon 72, p53 gene, PCR - RFLP, gastric cancer.

scholarly journals Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Koichi Hayano ◽  
Hiroki Watanabe ◽  
Takahiro Ryuzaki ◽  
Naoto Sawada ◽  
Gaku Ohira ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Stage Iv ◽  
R0 Resection ◽  
Conversion Surgery ◽  
First Line ◽  
Her2 Positive ◽  
Stage Iv Gastric Cancer ◽  
Gastric Cancer Patients ◽  
First Line Treatment

Abstract Background Since the ToGA trial, trastuzumab-based chemotherapy is the standard treatment for HER2 positive stage IV gastric cancer. However, it is not yet clear whether surgical resection after trastuzumab-based chemotherapy (conversion surgery) can improve survival of HER2 positive stage IV gastric cancer. The purpose of this study is to evaluate the prognostic benefit of conversion surgery in HER2 positive stage IV gastric cancer patients. Case presentation We retrospectively investigated the medical records of the patients with HER2 positive (IHC3(+) or IHC2(+)/FISH(+)) stage IV gastric cancer treated with trastuzumab-based chemotherapy as the first line treatment. Overall survival (OS) was compared between patients with conversion surgery and without. Eleven HER2 positive stage IV gastric cancer patients treated with trastuzumab-based chemotherapy as the first line treatment were evaluated. Response rate was 63.6%, and 6 of 11 patients could receive conversion surgery. R0 resection was achieved in four patients. In Kaplan–Meier analysis, patients who received conversion surgery showed significantly better OS than those without surgery (3-year survival rate, 66.7% vs. 20%, P = 0.03). The median OS of patients who achieved R0 resection is 51.8 months. Conclusions Conversion surgery might have a survival benefit for HER2 positive stage IV gastric cancer patients. If curative surgery is technically possible, conversion surgery could be a treatment option for HER2 positive stage IV gastric cancer.

Prognostic Indicators in Stage IV Surgically Treated Gastric Cancer Patients: A Retrospective Multi-Institutional Study

2018 ◽  
Vol 36 (4) ◽  
pp. 331-339
Author(s):  
Alberto Biondi ◽  
Domenico D’Ugo ◽  
Ferdinando Cananzi ◽  
Stefano Rausei ◽  
Federico Sicoli ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Residual Disease ◽  
Stage Iv ◽  
Long Term Results ◽  
Stage Iv Gastric Cancer ◽  
Short And Long Term ◽  
Gastric Cancer Patients

Introduction: The role of gastric resection in treating metastatic gastric adenocarcinoma is controversial. In the present study, we reviewed the short- and long-term outcomes of stage IV patients undergoing surgery. Methods: A retrospective review was conducted that assessed patients undergoing elective surgery for incurable gastric carcinoma. Short- and long-term results were evaluated. Results: A total of 122 stage IV gastric cancer patients were assessed. Postoperative mortality was 5.7%, and the overall rate of complications was 35.2%. The overall survival rate at 1 and 3 years was 58 and 19% respectively; the median survival was 14 months. Improved survival was observed for the factors age less than 60 years (p = 0.015), site of metastases (p = 0.022), extended lymph node dissection (p = 0.044), absence of residual disease after surgery (p = 0.001), and administration of adjuvant chemotherapy (p = 0.016). Multivariate analysis showed that residual disease and adjuvant chemotherapy were independent prognostic factors. Conclusions: The results of this study suggest that surgery combined with systemic chemotherapy in selected patients with stage IV gastric cancer can improve survival.

scholarly journals Serum leptin levels in gastric cancer patients and the relationship with insulin resistance

2015 ◽  
Vol 2 ◽  
pp. 346-352 ◽  
Author(s):  
Huseyin Begenik ◽  
Mehmet Aslan ◽  
Ahmet Cumhur Dulger ◽  
Habib Emre ◽  
Ahu Kemik ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Insulin Resistance ◽  
Cancer Patients ◽  
Serum Leptin ◽  
Gastric Cancer Patients ◽  
The Relationship

scholarly journals Monocyte Chemiluminescence Traits in Gastric Cancer

2021 ◽  
Vol 31 (2) ◽  
pp. 34-39
Author(s):  
O. V. Smirnova ◽  
A. A. Sinyakov ◽  
V. V. Tsukanov
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Gastric Adenocarcinoma ◽  
Stage Iv ◽  
Stage I ◽  
Control Cohort ◽  
Chemiluminescence Intensity ◽  
Stage Iv Gastric Cancer ◽  
Spontaneous Chemiluminescence ◽  
Gastric Cancer Patients

Aim. A study of monocyte chemiluminescent activity at variant stages of gastric cancer.Materials and methods. The study enrolled 90 gastric cancer patients and 70 healthy donors. Spontaneous and induced chemiluminescence in monocytes was assessed for 90 min with a “BLM 3607” 36-channel chemiluminescence analyser (Russia). Opsonized zymosan-induced chemiluminescence enhancement was measured as a ratio of the areas under the induced vs. spontaneous chemiluminescence curves, the activation index. Statistical significance was estimated with the Mann—Whitney criterion (p < 0.05).Results. The maximal spontaneous monocyte chemiluminescence intensity significantly decreased in stage IV gastric cancer patients compared to the control cohort (p = 0.035). Time to maximum in spontaneous chemiluminescence increased in all gastric cancer patients vs. control (p = 0.001), and in stage IV gastric cancer vs. stage I patients (p = 0.043). The areas under a curve in spontaneous and induced monocyte chemiluminescence increased in all gastric cancer patients vs. control (p = 0.001), and in stage IV gastric cancer vs. stage I patients (p = 0.037). The activation index was higher in all gastric cancer cases compared to control (p = 0.001).Conclusion. All patients with gastric adenocarcinoma, irrespective of the stage, revealed changes in the monocyte chemiluminescence activity, i.e. a longer time to maximum in spontaneous chemiluminescence and larger area under the curve of spontaneous and induced chemiluminescence, the activation index. Maximal monocyte spontaneous chemiluminescence intensity diminished in stage IV gastric cancer compared to the control cohort. Immune activity reflected in monocyte chemiluminescence correlates with the stage of gastric adenocarcinoma.

scholarly journals Study on the Relationship between Expression of LGR5 and Clinicopathological Characteristics in Gastric Cancer Patients

Health ◽  
2018 ◽  
Vol 10 (01) ◽  
pp. 159-169
Author(s):  
Xiulian Xu ◽  
Qijun Lv ◽  
Ping Xie ◽  
Shoujiang Wei ◽  
Chongshu Wang
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinicopathological Characteristics ◽  
Gastric Cancer Patients ◽  
The Relationship

Clinicopathologic features predicting HER2 overexpression in gastric cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15098-e15098
Author(s):  
Ji Soo Park ◽  
Minkyu Jung ◽  
Hye Ryun Kim ◽  
Sun Young Rha ◽  
Hyun Cheol Chung ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Pulmonary Metastasis ◽  
Stage Iv ◽  
Signet Ring Cell ◽  
P Value ◽  
Her2 Overexpression ◽  
Her2 Positive ◽  
Gastric Cancer Patients

e15098 Background: HER2-based therapy was found to improve survival outcome of patients with HER2-positive advanced gastric cancer. In gastric cancer, HER2 overexpression is commonly defined as IHC 3+ or IHC 2+/FISH amplification. Because positivity of HER2 overexpression is reported in below 20%, identifying the predictive clinical factors for the HER2 overexpression before the pathologic analysis may be helpful and cost-effective. Methods: From JAN 2005 to DEC 2010, 517 gastric cancer patients performed with HER2 IHC and/or FISH tests at Yonsei University College of Medicine were enrolled. Results: Among the 517 patients, 61 patients (11.8%) were confirmed as HER2 overexpression. Forty three out of stage IV, 258 patients (16.7%) and 18 out of 259 (6.9%) localized gastric cancer patients had HER2 overexpression (p <0.001). HER2 overexpression was more common in male (14.2% vs. 7.5% in female, p-value 0.024), moderately differentiated (26.4% vs. 11.1%, 8.9%, 4.9% and 5.9% in well differentiated, poorly differentiated, signet ring cell, and mucinous, retrospectively, p <0.001). Patients with elevated CEA (> 5.0 ng/mL vs. ≤ 5.0 ng/mL: 24.3% vs. 8.4%, p <0.001), metastasis to distant lymph node (with vs. without: 28.6% vs. 14.8%, p-value 0.042), without carcinomatosis (without vs. with: 21.2% vs. 11.6%, p-value 0.039) and pulmonary metastasis (with vs. without: 47.4% vs. 14.2%, p <0.001) also frequently had HER2-positive disease. In addition, high risk patients with 4 or more of the 7 features (metastatic disease, male, moderate differentiated adenocarcinoma, elevated CEA level, metastasis to distant lymph node, pulmonary metastasis, and without carcinomatosis) had 32.9% of HER2 positivity. (p <0.001). Conclusions: Those clinicopathologic factors may be helpful to predict the high likelihood of HER2 positive cases prior to pathologic confirmation in gastric cancer. Further molecular study for the HER2 overexpression is needed to clarify and explain this clinical phenomenon.

Sign in / Sign up

Export Citation Format

Share Document